Clinical trial
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
NCT00683475
Study timeline
Study start (unknown)2008-08-01Date precision: month
Registry last updated2014-10-16
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
IMC-A12BIOLOGICAL
MitoxantroneDRUG · verified · RxNorm: mitoxantrone
PrednisoneDRUG · verified · RxNorm: prednisone
IMC-1121B (ramucirumab)BIOLOGICAL
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
New YorkNew York, United States4HoustonTexas, United States2SeattleWashington, United States2ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1NashvilleTennessee, United States1ClevelandOhio, United States1PittsburghPennsylvania, United States1DurhamNorth Carolina, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00683475 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.